Literature DB >> 21979858

How do I deal with the axilla in patients with a positive sentinel lymph node?

Conrad B Falkson1.   

Abstract

OPINION STATEMENT: Optimal management of the axilla in a patient with a positive sentinel node biopsy is not yet defined.These patients usually have Breast Conserving Surgery and receive adjuvant systemic therapy and whole breast radiation.Treatment options for the axilla include: no further surgery with or without radiation completion axillary nodal dissection with or without radiation Radiation options in addition to whole breast radiation include axillary and supraclavicular nodal irradiation regional nodal irradiationincludes supraclavicular and internal mammary nodes Completion axillary dissection has been standard practice in patients with positive sentinel nodes. the number of involved nodes provides prognostic information. theoretically improves local control, but may be obviated by systemic chemotherapy. but avoidance of dissection may not adversely affect locoregional control or survival. dissection has significant morbidity so safe avoidance is desirable. There is little worldwide concordance on the use of radiation: whole breast radiation (commonly used after breast conserving surgery) may radiate the lower axilla supraclavicular radiation is most commonly recommended for patients with four or more nodes but may confer a survival benefit on patients with lower risk disease. adding nodal irradiation reduces local recurrence with only modest toxicity. Adjuvant systemic therapy provides a survival benefit for patients with nodal disease. Most will receive cytostatic chemotherapy containing an anthracycline and a taxane. Hormone therapy is appropriate for estrogen receptor positive disease. The extent to which systemic therapy controls microscopic nodal disease is unknown. Node positive patients should generally receive adjuvant chemotherapy.A small group of patients benefit from specific nodal therapy. Further studies are needed to better identify these patients.

Entities:  

Mesh:

Year:  2011        PMID: 21979858     DOI: 10.1007/s11864-011-0170-4

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  110 in total

1.  Breast cancer regional radiation fields for supraclavicular and axillary lymph node treatment: is a posterior axillary boost field technique optimal?

Authors:  Xiaochun Wang; Tse Kuan Yu; Mohammad Salehpour; Sean X Zhang; Tzouh Liang Sun; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-19       Impact factor: 7.038

2.  Supraclavicular nodal failure in patients with one to three positive axillary lymph nodes treated with breast conserving surgery and breast irradiation, without supraclavicular node radiation.

Authors:  Shruthi G Reddy; Krystyna D Kiel
Journal:  Breast J       Date:  2007 Jan-Feb       Impact factor: 2.431

3.  Effectiveness of axillary lymph node dissection in modified radical mastectomy with preservation of pectoral muscles.

Authors:  A Hultborn; L Hultén; B Roos; M Rosencrantz; C Rosengren B Ahrén
Journal:  Ann Surg       Date:  1974-03       Impact factor: 12.969

4.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Authors:  Joseph Ragaz; Ivo A Olivotto; John J Spinelli; Norman Phillips; Stewart M Jackson; Kenneth S Wilson; Margaret A Knowling; Christopher M L Coppin; Lorna Weir; Karen Gelmon; Nhu Le; Ralph Durand; Andrew J Coldman; Mohamed Manji
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

5.  Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients.

Authors:  O Mathiesen; J Carl; O Bonderup; J Panduro
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

6.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Authors:  M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

7.  Impact of axillary dissection on staging and regional control in breast tumors < or = 10 mm--the DBCG experience. The Danish Breast Cancer Cooperative Group (DBCG), Rigshisoutalet, Copenhagen, Denmark.

Authors:  C K Axelsson; F Rank; M Blichert-Toft; H T Mouridsen; M B Jensen
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

8.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

9.  Coverage of axillary lymph nodes in supine vs. prone breast radiotherapy.

Authors:  Michelle Alonso-Basanta; Jane Ko; Melissa Babcock; J Keith Dewyngaert; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-05       Impact factor: 7.038

10.  Treatment optimization using computed tomography-delineated targets should be used for supraclavicular irradiation for breast cancer.

Authors:  Raweewan Liengsawangwong; Tse-Kuan Yu; Tzouh-Liang Sun; Jeremy J Erasmus; George H Perkins; Welela Tereffe; Julia L Oh; Wendy A Woodward; Eric A Strom; Mohammad Salephour; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-01       Impact factor: 7.038

View more
  4 in total

1.  Risk Factors for Arm Lymphedema in a Cohort of Breast Cancer Patients Followed up for 10 Years.

Authors:  René Aloisio da Costa Vieira; Allini Mafra da Costa; Josue Lopes de Souza; Rafael Richieri Coelho; Cleyton Zanardo de Oliveira; Almir José Sarri; Renato José Affonso Junior; Gustavo Zucca-Matthes
Journal:  Breast Care (Basel)       Date:  2015-12-14       Impact factor: 2.860

Review 2.  The Lymphatic System in Disease Processes and Cancer Progression.

Authors:  Timothy P Padera; Eelco F J Meijer; Lance L Munn
Journal:  Annu Rev Biomed Eng       Date:  2016-02-05       Impact factor: 9.590

3.  A case of synchronous breast and bilateral lung cancers: literature review and considerations for radiation treatment planning.

Authors:  Chunzi Jenny Jin; Xiangyang Mei; Conrad B Falkson
Journal:  BJR Case Rep       Date:  2015-08-25

Review 4.  Quercetin as a Novel Therapeutic Approach for Lymphoma.

Authors:  Saiedeh Razi Soofiyani; Kamran Hosseini; Haleh Forouhandeh; Tohid Ghasemnejad; Vahideh Tarhriz; Parina Asgharian; Željko Reiner; Javad Sharifi-Rad; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-08-02       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.